What we want to be able to do is invest in new antibiotics in ways that actually encourage appropriate use and sales of those antibiotics, and that really is the challenge here.
Queremos invertir en antibióticos nuevos en maneras que promuevan el uso adecuado y la venta de dichos antibióticos, y ése es el verdadero reto.